Veterans’ RightsAn independent resource for veterans
← All decisions
Granted

The Board granted the restoration of a 20 percent rating for prostate cancer effective January 1, 2025, as the reduction was based on an inadequate VA examination and opinion.

The deciding factor: The decision was based on the inadequacy of the April 2024 VA examination and July 2024 addendum opinion, which were found to be contradictory.

Claimed conditions
prostate cancer
How they argued it
Direct service connection
Exposure basis
None
Rating assigned
20%
Decision date
October 2, 2025
Citation
A25085021

Veterans Law Judge

DAVID L. WIGHT

Decisions by this judge: 2,156 · Granted: 29% (granted or partly granted, in the vetted decisions on this site)

Judge attribution: 2025 complete; earlier years partial.

This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Look up the original decision on VA.gov (opens in a new tab) using citation A25085021.

What this means for you

A grant means the Board agreed the veteran was entitled to the benefit. Decisions like this show the kind of evidence and arguments that tend to succeed for claims like it.

What you can do next

Related decisions

Other Board decisions on a similar condition or argued the same way.

Free starter guide for your own claim

Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.

We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.

We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.

This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.